Cargando…
Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
PURPOSE: To assess whether combination therapy (CT) reduces retreatments when compared to ranibizumab monotherapy (RM), while safely maintaining similar vision outcomes. METHODS: In this 24-month trial, patients with age-related macular degeneration (AMD) were randomized to 1) quarter-fluence or 2)...
Autores principales: | Gallemore, Ron P, Wallsh, Josh, Hudson, Henry L, Ho, Allen C, Chace, Richard, Pearlman, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279866/ https://www.ncbi.nlm.nih.gov/pubmed/28182161 http://dx.doi.org/10.2147/OPTH.S119510 |
Ejemplares similares
-
Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK
por: Claxton, Lindsay, et al.
Publicado: (2014) -
Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Patients with Angioid Streaks
por: Lee, Jun Mok, et al.
Publicado: (2007) -
Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
por: Asahi, Masumi G, et al.
Publicado: (2020) -
Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration
por: Chhablani, Jay Kumar
Publicado: (2010) -
Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration
por: Tsuchihashi, Takashi, et al.
Publicado: (2013)